Copyright Reports & Markets. All rights reserved.

Global Lambert-Eaton Myasthenic Syndrome Treatment Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Lambert-Eaton Myasthenic Syndrome Treatment Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Potassium Channel Blockers (Amifampridine)
      • 1.4.3 Cholinesterase Inhibitor (Pyridostigmine)
      • 1.4.4 Immune Therapy
      • 1.4.5 Intravenous Immunoglobulin
      • 1.4.6 Plasmapheresis
    • 1.5 Market by Application
      • 1.5.1 Global Lambert-Eaton Myasthenic Syndrome Treatment Market Share by Application (2019-2025)
      • 1.5.2 Hospitals
      • 1.5.3 Ambulatory Surgical Centers
      • 1.5.4 Others
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Lambert-Eaton Myasthenic Syndrome Treatment Market Size
    • 2.2 Lambert-Eaton Myasthenic Syndrome Treatment Growth Trends by Regions
      • 2.2.1 Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Regions (2019-2025)
      • 2.2.2 Lambert-Eaton Myasthenic Syndrome Treatment Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Challenges
      • 2.3.4 Porter’s Five Forces Analysis

    3 Market Share by Key Players

    • 3.1 Lambert-Eaton Myasthenic Syndrome Treatment Market Size by by Players
      • 3.1.1 Global Lambert-Eaton Myasthenic Syndrome Treatment Revenue by by Players (2014-2019)
      • 3.1.2 Global Lambert-Eaton Myasthenic Syndrome Treatment Revenue Market Share by by Players (2014-2019)
      • 3.1.3 Global Lambert-Eaton Myasthenic Syndrome Treatment Market Concentration Ratio (CR5 and HHI)
    • 3.2 Lambert-Eaton Myasthenic Syndrome Treatment Key Players Head office and Area Served
    • 3.3 Key Players Lambert-Eaton Myasthenic Syndrome Treatment Product/Solution/Service
    • 3.4 Date of Enter into Lambert-Eaton Myasthenic Syndrome Treatment Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Type (2014-2019)
    • 4.2 Global Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Application (2014-2019)

    5 North America

    • 5.1 North America Lambert-Eaton Myasthenic Syndrome Treatment Market Size (2014-2019)
    • 5.2 Lambert-Eaton Myasthenic Syndrome Treatment Key Players in North America
    • 5.3 North America Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Type
    • 5.4 North America Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Application

    6 Europe

    • 6.1 Europe Lambert-Eaton Myasthenic Syndrome Treatment Market Size (2014-2019)
    • 6.2 Lambert-Eaton Myasthenic Syndrome Treatment Key Players in Europe
    • 6.3 Europe Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Type
    • 6.4 Europe Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Application

    7 China

    • 7.1 China Lambert-Eaton Myasthenic Syndrome Treatment Market Size (2014-2019)
    • 7.2 Lambert-Eaton Myasthenic Syndrome Treatment Key Players in China
    • 7.3 China Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Type
    • 7.4 China Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Application

    8 Japan

    • 8.1 Japan Lambert-Eaton Myasthenic Syndrome Treatment Market Size (2014-2019)
    • 8.2 Lambert-Eaton Myasthenic Syndrome Treatment Key Players in Japan
    • 8.3 Japan Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Type
    • 8.4 Japan Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Lambert-Eaton Myasthenic Syndrome Treatment Market Size (2014-2019)
    • 9.2 Lambert-Eaton Myasthenic Syndrome Treatment Key Players in Southeast Asia
    • 9.3 Southeast Asia Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Type
    • 9.4 Southeast Asia Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Application

    10 India

    • 10.1 India Lambert-Eaton Myasthenic Syndrome Treatment Market Size (2014-2019)
    • 10.2 Lambert-Eaton Myasthenic Syndrome Treatment Key Players in India
    • 10.3 India Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Type
    • 10.4 India Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Lambert-Eaton Myasthenic Syndrome Treatment Market Size (2014-2019)
    • 11.2 Lambert-Eaton Myasthenic Syndrome Treatment Key Players in Central & South America
    • 11.3 Central & South America Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Type
    • 11.4 Central & South America Lambert-Eaton Myasthenic Syndrome Treatment Market Size by Application

    12 International Players Profiles

    • 12.1 Allergan, Plc.
      • 12.1.1 Allergan, Plc. Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
      • 12.1.4 Allergan, Plc. Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019))
      • 12.1.5 Allergan, Plc. Recent Development
    • 12.2 Biomarin Pharmaceutical, Inc.
      • 12.2.1 Biomarin Pharmaceutical, Inc. Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
      • 12.2.4 Biomarin Pharmaceutical, Inc. Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019)
      • 12.2.5 Biomarin Pharmaceutical, Inc. Recent Development
    • 12.3 Catalyst Pharmaceuticals, Inc.
      • 12.3.1 Catalyst Pharmaceuticals, Inc. Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
      • 12.3.4 Catalyst Pharmaceuticals, Inc. Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019)
      • 12.3.5 Catalyst Pharmaceuticals, Inc. Recent Development
    • 12.4 F. Hoffman-La Roche Ltd.
      • 12.4.1 F. Hoffman-La Roche Ltd. Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
      • 12.4.4 F. Hoffman-La Roche Ltd. Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019)
      • 12.4.5 F. Hoffman-La Roche Ltd. Recent Development
    • 12.5 GlaxoSmithkline, Plc.
      • 12.5.1 GlaxoSmithkline, Plc. Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
      • 12.5.4 GlaxoSmithkline, Plc. Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019)
      • 12.5.5 GlaxoSmithkline, Plc. Recent Development
    • 12.6 Jacobus Pharmaceutical Company, Inc.
      • 12.6.1 Jacobus Pharmaceutical Company, Inc. Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
      • 12.6.4 Jacobus Pharmaceutical Company, Inc. Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019)
      • 12.6.5 Jacobus Pharmaceutical Company, Inc. Recent Development
    • 12.7 Kawasumi Laboratories, Inc.
      • 12.7.1 Kawasumi Laboratories, Inc. Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
      • 12.7.4 Kawasumi Laboratories, Inc. Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019)
      • 12.7.5 Kawasumi Laboratories, Inc. Recent Development
    • 12.8 Merck & Co., Inc.
      • 12.8.1 Merck & Co., Inc. Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
      • 12.8.4 Merck & Co., Inc. Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019)
      • 12.8.5 Merck & Co., Inc. Recent Development
    • 12.9 Mitsubishi Pharma Corporation
      • 12.9.1 Mitsubishi Pharma Corporation Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Lambert-Eaton Myasthenic Syndrome Treatment Introduction
      • 12.9.4 Mitsubishi Pharma Corporation Revenue in Lambert-Eaton Myasthenic Syndrome Treatment Business (2014-2019)
      • 12.9.5 Mitsubishi Pharma Corporation Recent Development

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Product (2019-2025)
    • 13.2 Market Size Forecast by Application (2019-2025)
    • 13.3 Market Size Forecast by Regions
    • 13.4 North America
    • 13.5 Europe
    • 13.6 China
    • 13.7 Japan
    • 13.8 Southeast Asia
    • 13.9 India
    • 13.10 Central & South America

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 15.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune disorder involving nerves and muscles that results in significant muscle weakness. It is often associated with certain types of cancer or other autoimmune disorders. It is caused by faulty nerve cells that fail to release sufficient amounts of acetylcholine, the chemical essential for the conduction of impulses between nerves and muscles. There are a number of treatments available for the disorder, but serious complications are possible.
      In 2018, the global Lambert-Eaton Myasthenic Syndrome Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Lambert-Eaton Myasthenic Syndrome Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Lambert-Eaton Myasthenic Syndrome Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

      The key players covered in this study
      Allergan, Plc.
      Biomarin Pharmaceutical, Inc.
      Catalyst Pharmaceuticals, Inc.
      F. Hoffman-La Roche Ltd.
      GlaxoSmithkline, Plc.
      Jacobus Pharmaceutical Company, Inc.
      Kawasumi Laboratories, Inc.
      Merck & Co., Inc.
      Mitsubishi Pharma Corporation

      Market segment by Type, the product can be split into
      Potassium Channel Blockers (Amifampridine)
      Cholinesterase Inhibitor (Pyridostigmine)
      Immune Therapy
      Intravenous Immunoglobulin
      Plasmapheresis

      Market segment by Application, split into
      Hospitals
      Ambulatory Surgical Centers
      Others

      Market segment by Regions/Countries, this report covers
      North America
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Lambert-Eaton Myasthenic Syndrome Treatment status, future forecast, growth opportunity, key market and key players.
      To present the Lambert-Eaton Myasthenic Syndrome Treatment development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Lambert-Eaton Myasthenic Syndrome Treatment are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now